tiprankstipranks
Laboratorios Farmaceuticos Rovi, SA (CH:41L)
:41L
Switzerland Market

Laboratorios Farmaceuticos Rovi (41L) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

41L Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Laboratorios
Farmaceuticos Rovi
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

41L Stock 12 Month Forecast

There Are No Analyst Ratings for CH:41L In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

41L Financial Forecast

41L Earnings Forecast

The previous quarter’s earnings for 41L were CHF1.38.
The previous quarter’s earnings for 41L were CHF1.38.

41L Sales Forecast

The previous quarter’s earnings for 41L were CHF180.16M.
The previous quarter’s earnings for 41L were CHF180.16M.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on CH:41L
Jefferies
Jefferies
CHF78.4CHF60.28
Hold
Reiterated
05/13/26
Jefferies Sticks to Their Hold Rating for Laboratorios Farmaceuticos Rovi (0ILL)
Kepler Capital  Analyst forecast on CH:41L
Kepler Capital
Kepler Capital
CHF84.51CHF77.93
Buy
Reiterated
05/06/26
Laboratorios Farmaceuticos Rovi (0ILL) Receives a Buy from Kepler Capital
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on CH:41L
Jefferies
Jefferies
CHF78.4CHF60.28
Hold
Reiterated
05/13/26
Jefferies Sticks to Their Hold Rating for Laboratorios Farmaceuticos Rovi (0ILL)
Kepler Capital  Analyst forecast on CH:41L
Kepler Capital
Kepler Capital
CHF84.51CHF77.93
Buy
Reiterated
05/06/26
Laboratorios Farmaceuticos Rovi (0ILL) Receives a Buy from Kepler Capital
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Laboratorios Farmaceuticos Rovi

3 Months
Pablo de RenteriaKepler Capital
Success Rate
11/23 ratings generated profit
48%
Average Return
-3.06%
Copying Pablo de Renteria's trades and holding each position for 3 Months would result in 47.83% of your transactions generating a profit, with an average return of -3.06% per trade.
1 Year
Pablo de RenteriaKepler Capital
Success Rate
11/23 ratings generated profit
48%
Average Return
+1.81%
Copying Pablo de Renteria's trades and holding each position for 1 Year would result in 47.83% of your transactions generating a profit, with an average return of +1.81% per trade.
2 Years
Pablo de RenteriaKepler Capital
Success Rate
13/23 ratings generated profit
57%
Average Return
+0.70%
Copying Pablo de Renteria's trades and holding each position for 2 Years would result in 56.52% of your transactions generating a profit, with an average return of +0.70% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

41L Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
1
1
1
1
0
Hold
1
2
1
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
2
3
2
2
0
In the current month, 41L has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 41L average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

41L Stock Forecast FAQ

What is CH:41L’s average 12-month price target, according to analysts?
Currently, no data Available
What is CH:41L’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for CH:41L, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is Laboratorios Farmaceuticos Rovi, SA a Buy, Sell or Hold?
      Currently, no data Available
      What is Laboratorios Farmaceuticos Rovi, SA’s share price target?
      Currently, no data Available
      What do analysts say about Laboratorios Farmaceuticos Rovi, SA?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of Laboratorios Farmaceuticos Rovi, SA?
      To buy shares of CH:41L, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.